Compound Access
Psilocybin
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.
Country GuideMedical AccessOff-label Medical
Country Access Report
Medical Access and Reimbursement in Argentina
Argentina has an established regulatory framework for specific psychedelic derivatives, specifically Esketamine, while maintaining strict prohibition for classic hallucinogens like Psilocybin and MDMA.
- Access Level
- Off-label Medical
- Compounds Covered
- 3
- Active Trials
- 0
Access by Compound
Compound-specific notes summarise what is realistically available through approved medical use, clinical research, exceptional access, or private care where the country report has verifiable information.
Strictly Illegal
Compound Access
Esketamine
Spravato (esketamine nasal spray) was approved by the National Administration of Medicines, Food and Medical Technology (ANMAT) in April 2021 for treatment-resistant depression #. Coverage is currently primarily through private health insurance (prepagas) and specific medical exceptions.
Compound Access
Ketamine
Ketamine is strictly regulated and authorized for anesthetic and analgesic use in hospital settings. Off-label use for psychiatric conditions is emerging in private clinics but is not standardly reimbursed.
Sources and Verification
Last updated 2 Mar 2026. Source links are drawn from citation annotations in the medical access and reimbursement guide.